[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Sakai H, Tanaka H, Katsurada T, Yoshida Y, Okamoto E, Ohno H: Angioimmunoblastic T-cell lymphoma initially presenting with replacement of bone marrow and peripheral plasmacytosis. Intern Med; 2007;46(7):419-24
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma initially presenting with replacement of bone marrow and peripheral plasmacytosis.
  • A 73-year-old man presented with lymphadenopathy, hepatosplenomegaly, and a variety of hematological and immunological abnormalities.
  • The bone marrow was replaced by polymorphic cellular infiltrates containing aggregates of CD10(+) T-cells.
  • Circulating lymphoplasmacytic/immunoblastic cells showed an early plasma cell immunophenotype on flow cytometric analysis.
  • Combination of these observations indicated that the underlying disorder of this patient was angioimmunoblastic T-cell lymphoma (AITL); postmortem pathology was consistent with progression of peripheral T-cell lymphoma.
  • Even in the absence of definitive lymph node biopsy, the appearance of the bone marrow and the peripheral blood can lead to the diagnosis of AITL.
  • [MeSH-major] Bone Marrow / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Plasma Cells / pathology
  • [MeSH-minor] Aged. Autopsy. Biopsy, Needle. Diagnosis, Differential. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. Male. Risk Assessment. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409610.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Chen W, Kesler MV, Karandikar NJ, McKenna RW, Kroft SH: Flow cytometric features of angioimmunoblastic T-cell lymphoma. Cytometry B Clin Cytom; 2006 May;70(3):142-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric features of angioimmunoblastic T-cell lymphoma.
  • BACKGROUND: The immunophenotypic features of angioimmunoblastic T-cell lymphoma (AILT) have not been well described.
  • CD10 was expressed by the neoplastic populations in 11 of 14 cases at diagnosis; in 3 of these 11 only a subpopulation of the neoplastic cells was CD10(+).
  • CD10 tended to be absent on neoplastic cells in staging bone marrows.
  • CONCLUSIONS: These results indicate the potential utility of flow cytometry in the diagnosis and follow-up of AILT.
  • [MeSH-major] Flow Cytometry / methods. Immunoblastic Lymphadenopathy / pathology. Immunophenotyping / methods. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Antigens, CD3 / analysis. Antigens, CD45 / analysis. Antigens, CD7 / analysis. Bone Marrow / pathology. Female. Follow-Up Studies. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neprilysin / analysis. Receptors, Complement 3d / analysis. Retrospective Studies. T-Lymphocytes / chemistry. T-Lymphocytes / metabolism. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 International Society for Analytical Cytology.
  • (PMID = 16572417.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, CD7; 0 / Receptors, Complement 3d; EC 3.1.3.48 / Antigens, CD45; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


3. Matsui K, Adachi M, Tominaga T, Shinohara K, Kamei T: Angioimmunoblastic T cell lymphoma associated with reversible myelofibrosis. Intern Med; 2008;47(21):1921-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T cell lymphoma associated with reversible myelofibrosis.
  • Biopsy of the lymph node demonstrated angioimmunoblastic T cell lymphoma (AITL) with the loss of normal architecture, proliferation of neoplastic T cells, small vessels mixed with eosinophils and plasma cells.
  • Aspiration of bone marrow was dry tap, and biopsy demonstrated myelofibrosis with increased proliferation of reticulin fiber.
  • After chemotherapy, remission of lymphoma was achieved.
  • The aspiration of bone marrow became possible, and the level of TGF-beta1 and PDGF AB showed normalization; thus, myelofibrosis was reversible.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Primary Myelofibrosis / diagnosis
  • [MeSH-minor] Humans. Lymphoma, T-Cell / complications. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / drug therapy. Male. Middle Aged

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981638.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Khokhar FA, Payne WD, Talwalkar SS, Jorgensen JL, Bueso-Ramos CE, Medeiros LJ, Vega F: Angioimmunoblastic T-cell lymphoma in bone marrow: a morphologic and immunophenotypic study. Hum Pathol; 2010 Jan;41(1):79-87
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma in bone marrow: a morphologic and immunophenotypic study.
  • Angioimmunoblastic T-cell lymphoma is known to frequently involve bone marrow.
  • However, the histologic and immunophenotypic features of angioimmunoblastic T-cell lymphoma at this site are poorly defined.
  • We assessed 27 bone marrow specimens involved by angioimmunoblastic T-cell lymphoma from 20 patients.
  • Histologically, bone marrow involvement was predominantly multifocal (74%) and exhibited a nodular pattern (78%), often associated with other patterns.
  • BCL-6 as a single antibody was difficult to interpret because many normal bone marrow cells are dimly positive, but BCL-6/CD3 dual staining highlighted BCL-6+ T-cells in all cases assessed.
  • Flow cytometry immunophenotyping revealed a CD3+CD10+ T-cell population in 2 (25%) of 8 cases assessed.
  • We conclude that the recognition and classification of angioimmunoblastic T-cell lymphoma in bone marrow are made difficult by the uncommon expression of CD10 (25%), rarity of follicular dendritic cells, and lack of CXCL13 expression at this site.
  • This is most likely attributable to the very different microenvironment of the bone marrow relative to lymph nodes and, in particular, the absence of follicles in bone marrow.
  • By contrast, programed death-1 immunohistochemical staining and double labeling using antibodies specific for BCL-6 and CD3 were helpful in appreciating the follicular T-helper cell immunophenotype of angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Bone Marrow Cells / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Chemokine CXCL13 / metabolism. DNA-Binding Proteins / metabolism. Female. Flow Cytometry. Humans. Immunophenotyping. Intercellular Signaling Peptides and Proteins / metabolism. Male. Middle Aged. Neprilysin / metabolism. Programmed Cell Death 1 Ligand 2 Protein. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19740519.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / DNA-Binding Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / PDCD1LG2 protein, human; 0 / Programmed Cell Death 1 Ligand 2 Protein; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


5. Cho YU, Chi HS, Park CJ, Jang S, Seo EJ, Huh J: Distinct features of angioimmunoblastic T-cell lymphoma with bone marrow involvement. Am J Clin Pathol; 2009 May;131(5):640-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct features of angioimmunoblastic T-cell lymphoma with bone marrow involvement.
  • We retrospectively reviewed the clinical and laboratory data and bone marrow (BM) histomorphologic features in 33 angioimmunoblastic T-cell lymphoma (AITL) cases.
  • Paraffin-embedded BM core biopsy specimens were reacted immunohistochemically with antibodies to pan-T-cell markers, CD20, CD10, CD21, and bcl-6.
  • The following features were more significant in patients with than without BM involvement: fever, hepatosplenomegaly, pleural effusion, elevated lactate dehydrogenase level, hypoalbuminemia, hyponatremia, hypocalcemia, anemia, circulating atypical cells, hypercellular marrow, and plasmacytosis in the BM.
  • Morphologic features included nodular or interstitial infiltration in a paratrabecular distribution, periodic acid-Schiff-positive intercellular materials, mixed infiltrates of T and B cells, presence of clear cells, and blood vessel proliferation.
  • Seven cases with BM involvement were interpreted as negative for lymphoma initially, mainly owing to insufficient information in nodal biopsy specimens.
  • Several clinical and laboratory features indicate BM involvement of AITL at diagnosis.
  • [MeSH-major] Bone Marrow / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19369622.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


6. Lee Y, Lee KW, Kim JH, Bang SM, Lee JS, Park BB, Kim WS, Suh C, Kang JH, Ryoo BY, Lee JH, Shin DB: Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma. Korean J Intern Med; 2008 Mar;23(1):30-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma.
  • BACKGROUND/AIMS: Epstein-Barr virus (EBV) is involved in the pathogenesis of angioimmunoblastic T-cell lymphoma (AILT), but its precise role and prognostic impact are not clear.
  • This study aimed to evaluate the incidence of EBV-postitivity in the tumor and bone marrow (BM) samples from AILT patients, and their correlations with the clinical variables and patient survival.
  • In 13 (48%) patients, gross tumor involvement was recognized by hematoxylin-eosin staining at the time of diagnosis.
  • [MeSH-major] Herpesvirus 4, Human / isolation & purification. Immunoblastic Lymphadenopathy / virology. Lymphoma, T-Cell / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow / virology. DNA, Viral / isolation & purification. Female. Humans. In Situ Hybridization. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):860-8 [17509983.001]
  • [Cites] Am J Clin Pathol. 2000 Aug;114(2):236-47 [10941339.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):805-11 [12153168.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Lancet Infect Dis. 2003 Mar;3(3):131-40 [12614729.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1328-37 [15044644.001]
  • [Cites] J Korean Med Sci. 2004 Apr;19(2):229-33 [15082896.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Int J Cancer. 1976 Feb 15;17(2):177-81 [175027.001]
  • [Cites] Blood. 1991 Feb 15;77(4):799-808 [1847084.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Blood. 1992 Jul 15;80(2):484-91 [1320954.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1804-12 [1327284.001]
  • [Cites] Histopathology. 1993 Feb;22(2):145-9 [8384155.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1063-9 [16079105.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1192-6 [16154842.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:260-6 [16304390.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):466-75; quiz 527 [16931587.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):716-22 [17454629.001]
  • [Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]
  • (PMID = 18363277.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2686953
  •  go-up   go-down


7. Yuan X, Chen F, Bi D, Zhao X, He Q, Li Q: [Clinicopathologic features and diagnosis of 18 patients with angioimmunoblastic T-cell lymphoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jun;34(6):523-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic features and diagnosis of 18 patients with angioimmunoblastic T-cell lymphoma].
  • OBJECTIVE: To explore the clinical and pathologic features of angioimmunoblastic T-cell lymphoma(AITL) and provide evidence for diagnosis.
  • RESULTS: Characteristic features at the presentation of AITL included generalized lymphadenopathy, fever, splenomegaly, and skin rashes with polyclonal hyper-gammaglobulinemia and other hematological abnormalities (such as Coombs-positive hemolytic anemia), which often involved the bone marrow and had well-described histologic features.
  • CONCLUSION: Repeated lymphadenbiopsy is helpful for AITL diagnosis.
  • Routine histological and immunohistochemical examinations (especially including CXCL13) play significant role in the diagnosis and differential diagnosis of AITL.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19587435.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13
  •  go-up   go-down


8. Lachenal F, Berger F, Ghesquières H, Biron P, Hot A, Callet-Bauchu E, Chassagne C, Coiffier B, Durieu I, Rousset H, Salles G: Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients. Medicine (Baltimore); 2007 Sep;86(5):282-92
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients.
  • We retrospectively analyzed 77 patients with pathologically diagnosed angioimmunoblastic T-cell lymphoma from a single city.
  • Average time between first symptoms of the disease and diagnosis was 3.6 months.
  • At diagnosis, peripheral nodes were present in all but 1 patient, and were generalized in 90% of cases.
  • Most patients presented with advanced disease at diagnosis (bone marrow involvement in 60% of cases).
  • Auto- or disimmune manifestations were reported in one-third of patients: autoimmune hemolytic anemia was present at diagnosis in 19% of patients and thrombocytopenic purpura in 7%.
  • Clonality was analyzed in lymph nodes in 47 patients: T-cell and B-cell clones were found in 45 (96%) and 20 (45%) patients, respectively.
  • The current study underlines the diversity of presenting manifestations of angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17873758.001).
  • [ISSN] 0025-7974
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / RNA, Viral
  •  go-up   go-down


9. Saito A, Miyazawa Y, Isoda A, Hatsumi N, Matsumoto M, Kojima M, Sawamura M: [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)]. Rinsho Ketsueki; 2008 Feb;49(2):82-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)].
  • We retrospectively analyzed the clinical course and prognosis of 11 patients with angioimmunoblastic T-cell Lymphoma (AILT).
  • As the initial therapy, 10 patients received combination chemotherapy and only 1 patient received autologous peripheral blood stem cell transplantation.
  • Patients with AILT demonstrating hyperplastic germinal centers and no bone marrow infiltration were able to achieve long-term survival.
  • [MeSH-major] Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341037.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Inoue D, Kimura T, Shimoji S, Mori M, Nagai Y, Tabata S, Kurata M, Matsushita A, Nagai K, Maruoka H, Yamashita E, Takahashi T: [Angioimmunoblastic T-cell lymphoma complicated by recurrent drug-induced agranulocytosis]. Rinsho Ketsueki; 2009 Feb;50(2):87-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma complicated by recurrent drug-induced agranulocytosis].
  • A 73-year-old man was hospitalized with fever, erythema, generalized superficial lymphadenopathy and marked neutropenia in July 2007.
  • Hematologic examination demonstrated a white blood cell count of 1,400/microl with 0% neutrophils, and 18% abnormal lymphocytes.
  • A bone marrow aspirate showed marked myeloid hypoplasia.
  • A diagnosis of drug-induced agranulocytosis was made.
  • Although neutrophil counts immediately returned to normal levels in response to filgrastim, fever, skin rash and systemic lymphadenopathy were all persistent.
  • Based on the histologic findings, PCR, and immunohistologic analyses, he was diagnosed with angioimmunoblastic T cell lymphoma (AILT) in leukemic state.
  • The response of the lymphoma to conventional chemotherapy (CHOP and ESHAP) was poor.
  • The treatment resulted in a partial remission of AILT including disappearance of circulating lymphoma cells.
  • [MeSH-major] Acetaminophen / adverse effects. Agranulocytosis / chemically induced. Analgesics, Non-Narcotic / adverse effects. Immunoblastic Lymphadenopathy / etiology. Lymphoma, T-Cell / etiology

  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19265300.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 0 / Immunosuppressive Agents; 362O9ITL9D / Acetaminophen; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


11. Grogg KL, Morice WG, Macon WR: Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol; 2007 Jun;137(5):416-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma.
  • Bone marrow (BM) biopsy is often performed early in the evaluation of patients with angioimmunoblastic T-cell lymphoma (AITL), and may be the first diagnostic tissue sample; yet the BM histopathology associated with this disease has not been well described.
  • As in lymph nodes, the lymphomatous infiltrate in some BMs contained numerous small or scattered large B cells, resembling either benign lymphoid aggregates or T cell rich large B cell lymphoma, respectively.
  • When BM biopsy preceded the diagnosis of AITL, these secondary changes were misinterpreted as chronic myeloproliferative disease (n = 2), or plasma cell dyscrasia (n = 2).
  • The spectrum of BM findings in AITL patients is important to recognise for early and accurate diagnosis in this disease.
  • [MeSH-major] Bone Marrow Examination. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] B-Lymphocytes / pathology. Chemokine CXCL13. Chemokines, CXC / analysis. Diagnosis, Differential. Eosinophils / pathology. Histiocytes / pathology. Humans. Immunohistochemistry. Lymphoma, B-Cell / pathology. Neprilysin / analysis. Red-Cell Aplasia, Pure / pathology. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488486.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Chemokines, CXC; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


12. Halene S, Zieske A, Berliner N: Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab. Nat Clin Pract Oncol; 2006 Mar;3(3):165-8; quiz 169
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab.
  • Initial symptoms resolved spontaneously without therapy, but fever recurred with associated arthralgias, myalgias, diffuse and worsening lymphadenopathy, splenomegaly, and bilateral pulmonary infiltrates.
  • INVESTIGATIONS: Physical examination, blood and urine cultures, MRI of the spine, echocardiogram, extensive serologies, serum and urine protein electrophoresis, immunofixation electrophoresis, bone-marrow aspiration and biopsy with flow cytometry, cytogenetics, and gene rearrangement studies, CT scan of the chest, abdomen and pelvis, whole-body PET, and lymph-node biopsy for histological examination, immunohistochemistry, and gene rearrangement studies.
  • DIAGNOSIS: Angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Immunoblastic Lymphadenopathy / drug therapy. Lymphoma, T-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520806.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


13. Jones B, Vun Y, Sabah M, Egan CA: Toxic epidermal necrolysis secondary to angioimmunoblastic T-cell lymphoma. Australas J Dermatol; 2005 Aug;46(3):187-91
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxic epidermal necrolysis secondary to angioimmunoblastic T-cell lymphoma.
  • A 67-year-old man presented with a history of lymphadenopathy, fevers and separate skin eruptions of erythrodermic spongiotic dermatitis initially and subsequent toxic epidermal necrolysis.
  • Initial lymph node biopsies showed non-specific granulomatous changes, and skin biopsies and bone marrow aspirate were not diagnostic.
  • Due to persisting lymphadenopathy, further lymph node biopsy led to the diagnosis of angioimmunoblastic T-cell lymphoma, a rare form of peripheral T-cell lymphoma with a poor prognosis.
  • At the time of diagnosis his condition deteriorated rapidly and he died soon after.
  • [MeSH-major] Head and Neck Neoplasms / complications. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications. Stevens-Johnson Syndrome / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008654.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous
  •  go-up   go-down


14. Tsochatzis E, Vassilopoulos D, Deutsch M, Filiotou A, Tasidou A, Archimandritis AJ: Angioimmunoblastic T-cell lymphoma-associated arthritis: case report and literature review. J Clin Rheumatol; 2005 Dec;11(6):326-8
MedlinePlus Health Information. consumer health - Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma-associated arthritis: case report and literature review.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare type of non-Hodgkin lymphoma with systemic manifestations, including fever, lymphadenopathy, rash, and rarely arthritis.
  • AITL-associated arthritis is an uncommon manifestation of angioimmunoblastic lymphoma that can mimic RA, especially when the typical systemic features of lymphoma are absent.
  • This type of arthritis should be included in the differential diagnosis of patients presenting with an inflammatory polyarthritis.
  • [MeSH-major] Arthritis / etiology. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications
  • [MeSH-minor] Biopsy. Bone Marrow / pathology. Diagnosis, Differential. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neck

  • Genetic Alliance. consumer health - Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16371804.001).
  • [ISSN] 1076-1608
  • [Journal-full-title] Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • [ISO-abbreviation] J Clin Rheumatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Munemasa S, Sakai A, Sasaki N, Okikawa Y, Mihara K, Kimura A: [Angioimmunoblastic T-cell lymphoma complicated with EBV-associated B-cell lymphoma]. Rinsho Ketsueki; 2005 Feb;46(2):127-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma complicated with EBV-associated B-cell lymphoma].
  • The immunohistochemical and pathologic findings from the biopsy specimens led to the diagnosis of angioimmunoblastic T-cell lymphoma (AILT) with a cluster of CD20-positive cells.
  • Furthermore, PCR of the IgH gene using DNA extracted from purified CD19-positive cells from the lymph nodes showed a monoclonal band, and it was different from that of purified CD138-positive cells from the bone marrow.
  • These findings indicated a diagnosis of angioimmunoblastic T-cell lymphoma complicated with EBV-associated B-cell lymphoma, and that immunodeficiency in AILT led to an expansion of EBV infected B-cells.
  • [MeSH-major] Epstein-Barr Virus Infections. Immunoblastic Lymphadenopathy / complications. Lymphoma, B-Cell / etiology
  • [MeSH-minor] Aged. Gene Rearrangement. Humans. Immunocompromised Host. Immunoglobulin Heavy Chains / genetics. Male. Molecular Diagnostic Techniques. Receptors, Antigen, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447706.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


16. Merchant SH, Amin MB, Viswanatha DS: Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma: Emphasis on phenotypic aberrancies for early diagnosis. Am J Clin Pathol; 2006 Jul;126(1):29-38

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma: Emphasis on phenotypic aberrancies for early diagnosis.
  • The morphologic features and immunophenotype of diagnostic nodal and bone marrow biopsy specimens were reviewed in 29 well-established cases of angioimmunoblastic T-cell lymphoma (AILT).
  • All cases showed a characteristic polymorphous lymphoid and inflammatory cell infiltrate along with stromal-vascular changes.
  • Unique architectural changes, including extranodal extension (83%), follicular dendritic cell proliferation (93%), and a distinctly marginalized distribution of residual B cells (67%) were observed.
  • Subsets of T cells with immunophenotypic abnormalities (CD10 coexpression or loss of pan-T-cell antigens CD3 and CD7) were identified in a majority of cases (96%).
  • Bone marrow involvement was present in 90% of patients with available biopsy specimens.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Immunophenotyping / methods. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Bone Marrow / metabolism. Bone Marrow / pathology. DNA, Neoplasm / analysis. Dendritic Cells, Follicular / metabolism. Dendritic Cells, Follicular / pathology. Early Diagnosis. Female. Flow Cytometry. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Middle Aged. Polymerase Chain Reaction. T-Lymphocyte Subsets / metabolism. T-Lymphocyte Subsets / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753608.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


17. Mizobe T, Tsukada J, Higashi T, Iwashige A, Ota T, Kawano I, Kubota A, Matsuura A, Morimoto H, Ogawa R, Toda Y, Tanaka Y: [Angioimmunoblastic T-cell lymphoma accompanied by pure red cell aplasia]. Rinsho Ketsueki; 2005 Mar;46(3):211-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma accompanied by pure red cell aplasia].
  • A 71-year-old woman was admitted in December 2002 because of lymphadenopathy, hepatosplenomegaly and pleural effusion.
  • Bone marrow aspiration showed an almost total absence of erythroblasts and no pathological cell proliferation.
  • The diagnosis of angioimmunoblastic T-cell lymphoma (AILT) was made based on the lymph node histological findings.
  • After combination chemotherapy (THP-COP), remission was achieved in both the pure red cell aplasia (PRCA) and AILT.
  • [MeSH-major] Immunoblastic Lymphadenopathy / complications. Red-Cell Aplasia, Pure / etiology

  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447717.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  • [Number-of-references] 10
  •  go-up   go-down


18. Lafaras C, Mandala E, Venizelos I, Valeri R, Barbetakis N, Bischiniotis T: Cardiac tamponade as primary manifestation of angioimmunoblastic T-cell lymphoma (AILT). Coexistence with malignant mesothelioma. Onkologie; 2008 Oct;31(10):546-8
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac tamponade as primary manifestation of angioimmunoblastic T-cell lymphoma (AILT). Coexistence with malignant mesothelioma.
  • Angioimmunoblastic T-cell lymphoma (AILT) is characterised by systemic disease usually presenting with generalised peripheral lymphadenopathy, hepatosplenomegaly, and bone marrow infiltration.
  • AILT diagnosis was confirmed by thoracoscopic mediastinal lymph node and bone marrow biopsy.
  • Despite the presence of pleural effusion, the diagnosis of mesothelioma was initially established by cytologic ex-amination of pericardial fluid, due to the patient's critical cardiac condition requiring prompt subxiphoid pericardiocentesis.
  • [MeSH-major] Cardiac Tamponade / diagnosis. Cardiac Tamponade / etiology. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma / complications. Lymphoma / diagnosis. Mesothelioma / complications. Mesothelioma / diagnosis


19. Wang FX, Zhang XJ, Pan L, Qiao SK, Guo XL, Dong ZR: [Angioimmunoblastic T-cell lymphoma with autoimmune hemolytic anemia and pure red cell aplasia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug;15(4):862-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma with autoimmune hemolytic anemia and pure red cell aplasia].
  • Angioimmunoblastic T-cell lymphoma (AILT) is a peripheral T-cell lymphoma often complicated autoimmune phenomena such as autoimmune cytopenia, and is a truly rare type of NHL.
  • In order to investigate the clinical features, pathological manifestation of this lymphoma, and to explore its therapy protocol, a 37-years old patient with AILT was investigated.
  • The routine blood examination, bone marrow smear, lymphonodus biopsy, Coombs test, flow cytometry for bone marrow mononuclear cells, serological test, immunochemistry method etc were performed for this patient.
  • Simultaneously, the bone marrow aspirate revealed erythroid aplasia.
  • The warm type autoimmune hemolytic anemia (AIHA) and pure red cell aplasia (PRCA) were co-existed.
  • In conclusion, the AITL patient complicated with AIHA and PRCA was successfully diagnosed, the lymphonode biopsy and bone marrow smear showed more significant, the chemotherapy protocol of CHOP-E can give some effect to cure such angioimmunoblastic T cell lymphoma.


20. Zhao WL, Liu YY, Plassa F, Jin XL, Wang L, Janin A, Shen ZX: [Analysis of overexpression of vascular endothelial growth factor-C in patients with angioimmunoblastic T-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2007 Oct;28(10):664-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of overexpression of vascular endothelial growth factor-C in patients with angioimmunoblastic T-cell lymphoma].
  • OBJECTIVE: To explore the vascular endothelial growth factor-C (VEGF-C) expression and its clinical significance in malignant lymphoma.
  • METHODS: Lymphoma cells were isolated by laser microdissection.
  • VEGF-C expression in lymphoma tissue and microdissected lymphoma cells was measured by realtime quantitative PCR.
  • RESULTS: Comparing with that in 8 patients with reactive lymphocyte hyperplasia, VEGF-C was overexpressed in angioimmunoblastic T-cell lymphoma, both in lymphoma tissue (n = 18, P = 0.0020) and in microdissected lymphoma cells (n = 10, P < 0.0001).
  • Increased VEGF-C level was associated with bone marrow infiltration (P = 0.0039), skin involvement (P = 0.0046) and high-risk international prognostic index (P = 0.0302).
  • CONCLUSION: The value of VEGF-C expression might be a biomarker of disease progression in angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / metabolism. Lymphoma, T-Cell / metabolism. Vascular Endothelial Growth Factor C / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399170.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


21. Choi JH, Oh YH, Park IK: A case of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma. Cancer Res Treat; 2010 Jun;42(2):115-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma.
  • Pure red cell aplasia is a bone marrow failure characterized by a progressive normocytic anemia and reticulocytopenia without leucopenia and thrombocytopenia.
  • However, pure red cell aplasia with angioimmunoblastic T cell lymphoma has rarely been reported.
  • Here we describe a 43-year-old woman with pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma.
  • A bone marrow biopsy revealed focal infiltration of abnormal lymphoid cells and absence of red cell precursors.
  • Splenic biopsy was compatible with angioimmunoblastic T-cell lymphoma.
  • Ultimately, diagnosis of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma was made.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Haematol. 1996;96(2):68-72 [8701703.001]
  • [Cites] Am J Hematol. 1994 Jun;46(2):72-8 [8172198.001]
  • [Cites] J R Soc Med. 1983 Oct;76(10):894-5 [6631867.001]
  • [Cites] Am J Hematol. 1999 Dec;62(4):259-60 [10589086.001]
  • [Cites] Biomed Pharmacother. 2003 Oct;57(8):326-32 [14568226.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] Haematologica. 1982 Nov-Dec;67(6):919-25 [6819197.001]
  • (PMID = 20622966.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2901080
  • [Keywords] NOTNLM ; Lymphoma / Pure / Red-cell aplasia / T-cell
  •  go-up   go-down


22. Bal M, Gujral S, Gandhi J, Shet T, Epari S, Subramanian PG: Angioimmunoblastic T-Cell lymphoma: a critical analysis of clinical, morphologic and immunophenotypic features. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):640-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-Cell lymphoma: a critical analysis of clinical, morphologic and immunophenotypic features.
  • BACKGROUND: Angioimmunoblastic T-cell lymphoma (AITL), a subtype of peripheral T-cell lymphoma (PTCL), is characterized by unique clinical and biological features.
  • Its diagnosis remains a challenge as clinical presentation as well as pathologic findings are frequently misleading.
  • Common clinical features included generalized lymphadenopathy (60%), hepatomegaly (70%), splenomegaly (50%), anemia (80%) and polyclonal hypergammaglobulinemia (100%).
  • Bone marrow infiltration was seen in 60% cases and 30% cases revealed plasmacytosis.
  • Absence of follicles, polymorphous infiltrate, extra-follicular follicular dendritic cell (FDC) proliferation, high endothelial venules (HEV) prominence and neoplastic T-cells were the diagnostic features of AITL.
  • CD10 positivity (47%), clear cells in the background (59%) admixture with large size CD20+ B-immunoblasts (35%) and bone marrow plasmacytosis (50%) were common observations.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia / diagnosis. Anemia / etiology. Antigens, CD20 / analysis. Female. Hepatomegaly / diagnosis. Hepatomegaly / etiology. Histocytochemistry. Humans. Hypergammaglobulinemia / diagnosis. Hypergammaglobulinemia / etiology. Immunohistochemistry. Lymphatic Diseases / diagnosis. Lymphatic Diseases / etiology. Male. Microscopy. Middle Aged. Neprilysin / analysis. Retrospective Studies. Sex Distribution. Splenomegaly / diagnosis. Splenomegaly / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045384.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


23. Rodríguez J, Conde E, Gutiérrez A, Arranz R, Gandarillas M, Leon A, Ojanguren J, Sureda A, Carrera D, Bendandi M, Moraleda J, Ribera JM, Albo C, Morales A, García JC, Fernández P, Cañigral G, Bergua J, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea: Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol; 2007 Apr;78(4):290-6
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
  • OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AIL) is a rare lymphoma with a poor prognosis and no standard treatment.
  • Here, we report our experiences with 19 patients treated with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) within the GELTAMO co-operative group between 1992 and 2004.
  • Prognostic factors associated with a poor outcome included bone marrow involvement, transplantation in refractory disease state, attributing more than one factor of the age-adjusted-International Prognostic Index, Pretransplant peripheral T-cell lymphoma (PTCL) Score or Prognostic Index for PTCL.
  • CONCLUSIONS: More than half of the patients with AIL that display unfavourable prognostic factors at diagnosis or relapse would be expected to be alive and disease-free after 3 yr when treated with HDC/ASCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell, Peripheral / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378891.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


24. Awaya N, Adachi A, Mori T, Kamata H, Nakahara J, Yokoyama K, Yamada T, Kizaki M, Sakamoto M, Ikeda Y, Okamoto S: Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma. Leuk Res; 2006 Aug;30(8):1059-62
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma.
  • Post-transplant lymphoproliferative disorder (PTLD) is a complication that can develop after either solid-organ or hematopoietic stem cell transplantation (HSCT).
  • T-cell PTLD is a rare disorder, especially following autologous HSCT.
  • Here we report a case of T-cell PTLD which occurred after autologous peripheral blood stem cell transplantation (PBSCT) for relapsed angioimmunoblastic T-cell lymphoma (AILT).
  • Our post-mortem study confirmed the marked proliferation of EBV-infected T-cells that differed from the original AILT clone and macrophages/histiocytes were observed in the marrow, liver, lymph nodes and lungs.
  • Phagocytosis was most evident in the bone marrow.
  • To the best of our knowledge, this is the first case of fulminant EBV-associated T-cell lymphoproliferative disorder (LPD) following autologous HSCT.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell, Peripheral / therapy. Lymphoproliferative Disorders / complications. Peripheral Blood Stem Cell Transplantation / adverse effects

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330097.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human
  •  go-up   go-down


25. Blom E, Heyning FH, Kroes WG: A case of angioimmunoblastic T-cell non-Hodgkin lymphoma with a neocentric inv dup(1). Cancer Genet Cytogenet; 2010 Oct 1;202(1):38-42
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of angioimmunoblastic T-cell non-Hodgkin lymphoma with a neocentric inv dup(1).
  • Acquired neocentromeres have been described in a particular class of lipomatous tumors (atypical lipomas and well-differentiated liposarcomas; ALP-WDLPS), three cases of acute myeloid leukemia (AML), one case of non-Hodgkin lymphoma (NHL), and one case of lung carcinoma.
  • Here, we report on a 66-year-old male with angioimmunoblastic T-cell NHL.
  • Cytogenetic analysis of his bone marrow showed multiple aberrations, including the presence of a supernumerary chromosome.
  • To our knowledge, this is the second reported case of NHL (both T-cell) with the presence of a neocentromere.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Inversion. Chromosomes, Human, Pair 1. Gene Duplication. Immunoblastic Lymphadenopathy / genetics. Lymphoma, T-Cell / genetics
  • [MeSH-minor] Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Male. Neoplasms, Second Primary. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20804919.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


26. Piccaluga PP, Agostinelli C, Gazzola A, Mannu C, Bacci F, Sabattini E, Pileri SA: Prognostic markers in peripheral T-cell lymphoma. Curr Hematol Malig Rep; 2010 Oct;5(4):222-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic markers in peripheral T-cell lymphoma.
  • Based on their own experience and knowledge of the literature, the authors review the pathobiological characteristics of peripheral T-cell lymphomas (PTCLs), focusing on the available prognostic indicators.
  • However, it is not so satisfactory for the two commonest PTCLs, PTCL not otherwise specified (PTCL/NOS) and angioimmunoblastic T-cell lymphoma (AITL), for which novel scores, possibly based on the biologic features of the tumors, have been explored.
  • An Italian cooperative group proposed a revision of the IPI for PTCL unspecified (PTCL-U), the Prognostic Index for PTCL-U (PIT), which includes age, performance status, LDH, and bone marrow involvement.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / diagnosis
  • [MeSH-minor] Age Factors. Bone Marrow / pathology. Gene Expression Profiling. Humans. Lactate Dehydrogenases / metabolism. Prognosis. Severity of Illness Index

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2009 Jul;94(7):1036-7 [19508975.001]
  • [Cites] Br J Haematol. 2010 Feb;148(3):402-12 [19863542.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1026-36 [19965671.001]
  • [Cites] Blood. 2010 Feb 11;115(6):1226-37 [19965620.001]
  • [Cites] J Clin Oncol. 2010 Mar 20;28(9):1583-90 [20159827.001]
  • [Cites] N Engl J Med. 2010 Apr 15;362(15):1417-29 [20393178.001]
  • [Cites] Ann Oncol. 2010 May;21(5):1032-40 [19850638.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90 [12182990.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2213-9 [12750155.001]
  • [Cites] Blood. 2004 Jan 1;103(1):216-21 [12933580.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1837-48 [15111330.001]
  • [Cites] Blood. 2004 Jul 1;104(1):243-9 [15031209.001]
  • [Cites] Cancer. 2004 Jun 25;102(3):174-85 [15211477.001]
  • [Cites] Curr Treat Options Oncol. 2004 Aug;5(4):289-303 [15233906.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):4971-82 [15297397.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1097-107 [15195107.001]
  • [Cites] Leuk Res. 2004 Dec;28(12):1287-92 [15475070.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):375-87 [15494863.001]
  • [Cites] Histopathology. 1993 Apr;22(4):303-10 [8514273.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):909-16 [8101471.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Anal Quant Cytol Histol. 1996 Oct;18(5):337-44 [8908304.001]
  • [Cites] Histopathology. 2001 Mar;38(3):250-70 [11260307.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):821-9 [9217183.001]
  • [Cites] Cell Prolif. 1997 Jan;30(1):37-47 [9332493.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):973-8 [9402170.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):849-55 [9789607.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Anat Pathol. 1998;3:77-145 [10389582.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):849-55 [10414505.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):440 [15925824.001]
  • [Cites] Hematology. 2005 Jun;10(3):237-45 [16019472.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1063-9 [16079105.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):29-38 [16173960.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2254-63 [16270046.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):612-8 [16380410.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1560-70 [16288225.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4500-7 [16484591.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4163-9 [16902151.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2156-64 [17077326.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Haematologica. 2007 Apr;92(4):566-7 [17488672.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):38-44 [17536305.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3250-4 [17545530.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3321-9 [17577022.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3345-51 [17634410.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10703-10 [18006812.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] J Clin Pathol. 2008 Nov;61(11):1160-7 [18755717.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1071-4 [18955564.001]
  • [Cites] Histopathology. 2009 Mar;54(4):478-85 [19309400.001]
  • [Cites] Ann Oncol. 2009 Apr;20(4):715-21 [19150954.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3931-7 [19029440.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4016-26 [19131553.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):583-92 [9261528.001]
  • [ErratumIn] Curr Hematol Malig Rep. 2010 Oct;5(4):239
  • (PMID = 20690003.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.- / Lactate Dehydrogenases
  • [Other-IDs] NLM/ PMC2948168
  •  go-up   go-down


27. Yamamoto H, Miwa H, Kato Y, Nakamura S, Hara K, Nitta M: Angioimmunoblastic T cell lymphoma with an unusual proliferation of Epstein-Barr virus-associated large B cells arising in a patient with progressive systemic sclerosis. Acta Haematol; 2005;114(2):108-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T cell lymphoma with an unusual proliferation of Epstein-Barr virus-associated large B cells arising in a patient with progressive systemic sclerosis.
  • We report an unusual case of angioimmunoblastic T cell lymphoma arising in the setting of 5 years of immunosuppressive treatment for progressive systemic sclerosis.
  • Southern blot study demonstrated the clonal rearrangement of T cell receptor beta-chain gene, but not of immunoglobulin heavy chain gene.
  • Phenotypical examination of the lymph node also revealed the predominance of CD4+ T cells in addition to the proliferation of follicular dendritic cells, but no light chain restriction in large B cell components.
  • In the clinical and laboratory aspects, neutrophilia (15.8 x 10(9)/l) and plasmacytosis (40%) in bone marrow were noted, which were considered to be closely related to elevated serum granulocyte colony-stimulating factor, interleukin (IL)-4 and IL-6.
  • Based on the combined data described here, our preferred diagnosis was angioimmunoblastic T cell lymphoma with Epstein-Barr virus-associated B cell lymphoproliferative disorder, the pathogenesis of which was suggested to be closely associated with immunosuppressive treatment for progressive systemic sclerosis.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / pathology. Scleroderma, Diffuse / pathology

  • Genetic Alliance. consumer health - Diffuse Scleroderma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16103635.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


28. Tong H, Ren Y, Qian W, Xiao F, Mai W, Meng H, Jin J: Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China. Int J Hematol; 2009 Oct;90(3):303-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China.
  • We reviewed 173 patients with an initial diagnosis of peripheral T-cell non-Hodgkin lymphoma (PTCL) and compared the patients with bone marrow involvement (BMI) to those without to have a better understanding of the clinical characteristics, treatments, survival and prognosis of PTCLs with BMI.
  • We found that 40% (70/173) of the patients had BMI, and its frequency was 64% in angioimmunoblastic T-cell lymphoma (TCL), 46% in PTCL unspecified, 29% in anaplastic large T-cell lymphoma, 23% in extranodal NK/T-cell lymphoma and 13% in enteropathy-type TCL.
  • In the BMI group, 36% of patients had lymphoma-associated hemophagocytic syndrome (LAHS), compared with 8% of the patients without BMI (8/103, P < 0.001).
  • The median survival time of the 14 patients subjected to chemotherapy combined with L: -asparaginase was 365 days and that of the 7 patients undergoing hemopoietic stem cell transplantation (HSCT) was 575 days.
  • We conclude that patients with PTCLs with BMI on initial diagnosis usually have hemaphagocytic syndrome and poor prognosis.
  • BMI without lymphadenopathy is a patent clinical feature in most PTCLs.
  • Patients with anemia on initial diagnosis in the BMI group usually have poor prognosis than those without.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Lymphohistiocytosis, Hemophagocytic / drug therapy. Lymphohistiocytosis, Hemophagocytic / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. ASPARAGINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Feb 1;99(3):815-21 [11806981.001]
  • [Cites] Haematologica. 1997 Mar-Apr;82(2):171-7 [9175321.001]
  • [Cites] Histol Histopathol. 2002 Apr;17 (2):539-54 [11962758.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Br J Haematol. 2004 Jan;124(1):4-14 [14675403.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):140-54 [15461619.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):151-9 [17387300.001]
  • [Cites] Eur J Cancer. 2002 Jan;38(1):75-81 [11750843.001]
  • [Cites] J Korean Med Sci. 2004 Apr;19(2):229-33 [15082896.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):342-9 [14716770.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] Am J Clin Pathol. 1995 Jan;103(1):82-9 [7817951.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1278-82 [17475910.001]
  • [Cites] Br J Haematol. 1985 Oct;61(2):203-13 [4041367.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2000 Nov;21(11):577-9 [11225247.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):241-9 [12688340.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1601-8 [15378507.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Leuk Lymphoma. 2008 Jan;49(1):81-7 [18203016.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2007 Jul;28(7):454-7 [18072627.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):849-55 [9789607.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):331-8 [2050367.001]
  • (PMID = 19728028.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7006-34-0 / Asparagine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


29. Kako S, Izutsu K, Ota Y, Minatani Y, Sugaya M, Momose T, Ohtomo K, Kanda Y, Chiba S, Motokura T, Kurokawa M: FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol; 2007 Oct;18(10):1685-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET in T-cell and NK-cell neoplasms.
  • BACKGROUND: A growing number of studies demonstrate the utility of (18)fluoro-2-deoxyglucose positron emission tomography (FDG-PET) in the management of malignant lymphoma.
  • The results of FDG-PET, however, have not been studied extensively for T-cell and natural killer (NK)-cell neoplasms.
  • PATIENTS AND METHODS: We retrospectively evaluated pretreatment FDG-PET scans in 41 patients with T/NK-cell neoplasms diagnosed according to the World Health Organization (WHO) classification.
  • Histological subtypes frequently included were peripheral T-cell lymphoma, unspecified (PTCLu, n = 11), extranodal NK/T-cell lymphoma, nasal type (ENKL, n = 8), primary cutaneous anaplastic large cell lymphoma (C-ALCL, n = 5), and angioimmunoblastic T-cell lymphoma (AILT, n = 4).
  • RESULTS: FDG-PET detected a lymphoma lesion in at least one site in 36 out of 41 patients.
  • The positive rate of FDG-PET for bone marrow involvement was only 20%.
  • CONCLUSION: T/NK-cell neoplasms incorporated in this study were generally FDG-avid except for cutaneous lesions and bone marrow involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17716987.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


30. Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T, Takase K, Henzan H, Kato K, Takenaka K, Fukuda T, Harada N, Nagafuji K, Teshima T, Akashi K, Harada M, Eto T, Fukuoka Blood and Marrow Transplantation Group: Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant; 2010 Feb;45(2):311-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group.
  • Peripheral T-cell lymphoma (PTCL) is generally characterized by poor prognosis after conventional chemotherapy compared with aggressive B-cell lymphoma.
  • Eleven patients were histologically typed as angioimmunoblastic, nine as anaplastic large-cell lymphoma, seven as natural killer/T-cell lymphoma and twelve as PTCL unspecified.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / therapy. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597416.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Agostinelli C, Piccaluga PP, Went P, Rossi M, Gazzola A, Righi S, Sista T, Campidelli C, Zinzani PL, Falini B, Pileri SA: Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. J Clin Pathol; 2008 Nov;61(11):1160-7
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies.
  • Peripheral T cell lymphomas (PTCL) account for about 12% of lymphoid tumours worldwide.
  • In contrast to B cell lymphomas, PTCL have been the subject of only a limited number of studies to elucidate their pathobiology and identify novel pharmacological approaches.
  • PTCL/NOS are characterised by erratic expression of T cell associated antigens, including CD4 and CD52, which have recently been proposed as targets for ad hoc immunotherapies.
  • Gene expression profiling studies have revealed that PTCL/NOS derive from activated T lymphocytes, more often of the CD4+ type, and bear a signature composed of 155 genes and related products that play a pivotal role in cell signalling transduction, proliferation, apoptosis and matrix remodelling.
  • This observation seems to pave the way for the use of innovative drugs such as tyrosine kinase and histone deacetylase inhibitors whose efficacy has been proven in PTCL primary cell cultures.
  • Gene expression profiling also allows better distinction of PTCL/NOS from angioimmunoblastic T cell lymphoma, the latter being characterised by follicular T helper lymphocyte derivation and CXCL13, PD1 and vascular endothelial growth factor expression.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Gene Expression Profiling. Humans. Phenotype. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Quant Cytol Histol. 1996 Oct;18(5):337-44 [8908304.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):583-92 [9261528.001]
  • [Cites] Cell Prolif. 1997 Jan;30(1):37-47 [9332493.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):973-8 [9402170.001]
  • [Cites] J Pathol. 1997 Dec;183(4):432-9 [9496260.001]
  • [Cites] J Biochem. 1998 May;123(5):767-76 [9562604.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):643-55 [9630171.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):24015-23 [15044484.001]
  • [Cites] Cancer. 2004 Jun 25;102(3):174-85 [15211477.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):68-78 [15210760.001]
  • [Cites] Curr Treat Options Oncol. 2004 Aug;5(4):289-303 [15233906.001]
  • [Cites] Int Immunol. 2004 Aug;16(8):1109-24 [15210650.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):4971-82 [15297397.001]
  • [Cites] Leuk Res. 2004 Dec;28(12):1287-92 [15475070.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):334-43 [15480768.001]
  • [Cites] Am J Pathol. 1986 Mar;122(3):392-7 [3082212.001]
  • [Cites] J Immunol. 1986 Jun 15;136(12):4480-6 [3086432.001]
  • [Cites] Am J Pathol. 1987 May;127(2):279-87 [3555102.001]
  • [Cites] Br J Haematol. 1987 Sep;67(1):19-24 [3499172.001]
  • [Cites] Blood. 1988 Aug;72(2):413-21 [3261178.001]
  • [Cites] Blood. 1988 Sep;72(3):1000-6 [3046680.001]
  • [Cites] Lancet. 1988 Dec 17;2(8625):1394-9 [2904526.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):549-56 [2849301.001]
  • [Cites] Mod Pathol. 2007 Jun;20(6):632-7 [17431414.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Jul;16(7):1111-20 [17594194.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1059-66 [17640856.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3321-9 [17577022.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2316-23 [17581918.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9945-53 [17942927.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3345-51 [17634410.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10703-10 [18006812.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):396-7 [18245132.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Oncogene. 2002 Jun 27;21(28):4462-70 [12080476.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):454-60 [12216074.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3891-7 [12228210.001]
  • [Cites] Oncogene. 2002 Nov 21;21(53):8178-85 [12444554.001]
  • [Cites] Ann Hematol. 2002 Nov;81(11):646-50 [12454703.001]
  • [Cites] Am J Clin Pathol. 1989 Feb;91(2):152-8 [2464922.001]
  • [Cites] Am J Pathol. 1990 May;136(5):1093-9 [2161617.001]
  • [Cites] Hum Pathol. 1990 Nov;21(11):1117-25 [2227919.001]
  • [Cites] Cancer. 1991 May 15;67(10):2566-78 [1826629.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1259-67 [1739925.001]
  • [Cites] Cancer. 1992 May 15;69(10):2571-82 [1568182.001]
  • [Cites] Histopathology. 1993 Apr;22(4):303-10 [8514273.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8696-704 [12483522.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):319-24 [12527929.001]
  • [Cites] Oncogene. 2003 Jan 23;22(3):343-50 [12545155.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25808-15 [12736251.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1042-50 [12689942.001]
  • [Cites] Eur J Biochem. 2003 Aug;270(16):3408-21 [12899698.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):33801-8 [12826661.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2213-9 [12750155.001]
  • [Cites] Genome Biol. 2003;4(10):R70 [14519205.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7762-73 [14586402.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):767-77 [14608905.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1513-22 [14657710.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):54-61 [14707864.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):146-53 [14743220.001]
  • [Cites] Bone Marrow Transplant. 2004 Feb;33(4):405-10 [14676776.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):849-55 [9789607.001]
  • [Cites] Curr Hematol Rep. 2005 Jan;4(1):23-30 [15610656.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):206-14 [15668271.001]
  • [Cites] Mol Endocrinol. 2005 Feb;19(2):527-39 [15486044.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):440 [15925824.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2254-63 [16270046.001]
  • [Cites] J Immunol. 2005 Dec 15;175(12):7837-47 [16339519.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):1867-79 [16373702.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1560-70 [16288225.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):490-4 [16625095.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4500-7 [16484591.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 5):S44-52 [16720203.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1101-7 [16680156.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1174-82 [16675713.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7174-9 [17145843.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4163-9 [16902151.001]
  • [Cites] Hematol Oncol. 2006 Dec;24(4):175-80 [16783841.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2156-64 [17077326.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):117-21 [17325855.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Haematologica. 2007 Apr;92(4):566-7 [17488672.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):117-22 [10632495.001]
  • [Cites] Virchows Arch. 2000 Apr;436(4):357-64 [10834539.001]
  • [Cites] Mod Pathol. 2000 Jul;13(7):766-72 [10912936.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5603-7 [11059746.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):395-400 [11224611.001]
  • [Cites] Mod Pathol. 2001 Feb;14(2):105-10 [11235901.001]
  • [Cites] Histopathology. 2001 Mar;38(3):250-70 [11260307.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11414-9 [11150309.001]
  • [Cites] J Biol Chem. 2001 Jan 26;276(4):2802-7 [11060313.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 1;128(1):1-6 [11454421.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Int J Hematol. 2001 Dec;74(4):442-6 [11794701.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):935-42 [14990650.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1837-48 [15111330.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):909-16 [8101471.001]
  • [Cites] Blood. 1993 Aug 1;82(3):807-12 [7687895.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Virchows Arch. 1994;425(1):25-32 [7921409.001]
  • [Cites] J Hematother. 1994 Spring;3(1):15-31 [7922004.001]
  • [Cites] Am J Clin Pathol. 1994 Oct;102(4):483-9 [7524302.001]
  • (PMID = 18755717.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 113
  • [Other-IDs] NLM/ PMC2582342
  •  go-up   go-down


32. Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG: Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant; 2008 Jul;14(7):741-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.
  • The peripheral T cell lymphomas (PTCL) carry a worse prognosis compared to B cell non-Hodgkin lymphoma.
  • There is no uniform standard therapy for PTCL, and autologous hematopoietic cell transplant (AHCT) is often offered as consolidation in first remission or at relapse because of the poor outcomes with conventional therapy.
  • Fifty-three cases were identified consisting of systemic anaplastic large cell (n = 18), PTCL unspecified (n = 17), angioimmunoblastic (n = 9), nasal type extranodal NK/T (n = 7), hepatosplenic (n = 2), and adult T cell leukemia/lymphoma (n = 1).
  • Histology, age, sex, stage, B symptoms, bone marrow involvement, and duration of first response did not significantly affect PFS or OS.

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol J. 2004;5(4):304-11 [15297846.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(5):443-50 [17589529.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1628-37 [3772416.001]
  • [Cites] Blood. 1995 Jun 1;85(11):3334-41 [7538824.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Bone Marrow Transplant. 1999 Jul;24(2):153-61 [10455343.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Bone Marrow Transplant. 2001 Apr;27(7):711-6 [11360110.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):978-85 [12648067.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jul;12(7):703-11 [16785059.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):202-7 [16759221.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):439-47 [17233846.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):652-7 [17229774.001]
  • [Cites] Ann Hematol. 2007 Jun;86(6):435-42 [17256144.001]
  • [Cites] Eur J Haematol. 2007 Jul;79(1):32-8 [17598836.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(3):239-43 [17530000.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1067-74 [17640855.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2261-7 [15512815.001]
  • (PMID = 18541192.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA049605-15; United States / NCI NIH HHS / CA / P01 CA049605; United States / NCI NIH HHS / CA / P01 CA049605-15
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS232367; NLM/ PMC2980839
  •  go-up   go-down


33. Sonnen R, Schmidt WP, Müller-Hermelink HK, Schmitz N: The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol; 2005 May;129(3):366-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas.
  • The World Health Organization (WHO) lymphoma classification recognises anaplastic large cell lymphoma (ALCL), angioimmunoblastic lymphoma (AIL) and peripheral T-cell lymphoma, unspecified (PTCU) as nodal mature T-cell lymphomas.
  • To a large extent, the IPI score explains the differences in survival between histological subtypes of nodal mature T-cell lymphomas.
  • The IPI may therefore be used for risk stratification in clinical trials to identify patients who would benefit most from new treatment strategies, such as high-dose chemotherapy followed by stem cell or bone marrow transplantation.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis. Severity of Illness Index
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Marrow Transplantation. Cause of Death. Epidemiologic Methods. Female. Hematopoietic Stem Cell Transplantation. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy. Male. Middle Aged. Neoplasms, Second Primary. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842660.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. Yamazaki T, Sawada U, Kura Y, Ito T, Takeuchi J, Hatta Y, Aikawa S, Takei K, Ishizuka H, Saiki M, Uenogawa K: Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study. Acta Haematol; 2006;116(2):90-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study.
  • We investigated the efficacy of a dose-intensified double-CHOP regimen followed by high-dose chemotherapy with or without peripheral blood stem cell transplantation (PBSCT) in 11 patients with four types of peripheral T-cell lymphoma (PTCL).
  • All angioimmunoblastic T-cell lymphoma (AILT) and subcutaneous panniculitis-like T-cell lymphoma (SPTCL) patients achieved CR; 5 of 6 have remained disease free for more than 3 years.
  • The patient with hepatosplenic lymphoma did not achieve CR even after PBSCT and underwent allogenic bone marrow transplantation (allo-BMT).
  • However, allo-BMT should be considered for high-risk of PTCLu and hepatosplenic T-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / drug therapy


35. Kalyan K, Basu D, Soundararaghavan J: Immunohistochemical typing of non-Hodgkin's lymphoma-comparing working formulation and WHO classification. Indian J Pathol Microbiol; 2006 Apr;49(2):203-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical typing of non-Hodgkin's lymphoma-comparing working formulation and WHO classification.
  • The recent WHO classification of non-Hodgkin's lymphoma is based on the morphology and immunohistochemical expression of the lymphoma cells and to a lesser extent, on the molecular and cytogenetic findings.
  • Fifty-three cases of non-Hodgkin's lymphoma were included in the study.
  • Twenty two patients had peripheral blood and/or bone marrow involvement.
  • The two most common types encountered were diffuse large cell lymphoma and small lymphocytic lymphoma.
  • 38 cases (72%) showed B cell expression and 12 cases (22.5%) showed T cell expression.
  • B-cell diffuse large cell lymphoma (26%) was found to be the predominant B cell non-Hodgkin's lymphoma.
  • The commonest T-cell lymphoma was T lymphoblastic lymphoma (67%) followed by peripheral T cell angioimmunoblastic lymphoma (25%).
  • Immunohistochemistry is a useful and necessary diagnostic modality and helps subdivide prognostically different types of non-Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / classification

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933715.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3
  •  go-up   go-down


36. Niitsu N, Okamoto M, Nakamine H, Aoki S, Motomura S, Hirano M: Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol; 2008 Sep;26(3):152-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
  • We studied the clinico-pathologic features and treatment outcome of patients with peripheral T-cell lymphoma (PTCL).
  • This study included 215 patients with T/natural killer (NK)-cell lymphoma, including 59 with PTCL-unspecified (PTCL-U), 42 with angioimmunoblastic T-cell lymphoma (AILT) and 20 with anaplastic large-cell lymphoma (ALCL).
  • Most of the analyses were performed on patients with AILD, ALCL and PTCL-U.
  • The 5-year PFS and OS rates among patients who received CHOP therapy, CyclOBEAP [cyclophosphamide (CPA), vincristine (VCR), bleomycine, etoposide, doxorubicin (DXR), prednisone (PDN)] therapy or autologous stem cell transplantation were: 22 and 25.7%, 59 and 61.7% or 33.3 and 60%, respectively.
  • These results indicate that the presence of bone marrow (BM) involvement is an independent prognostic factor which may predict both OS and PFS.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 John Wiley & Sons, Ltd.
  • (PMID = 18395866.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


37. Zhang LX, Ye J, Lu TH, Jiang GN, Xiao W, Zhu XJ, Chen YB, Xing TJ, Wu ZD, Huang JX: [Immunophenotype analysis on neoplastic cells in bone marrow and peripheral blood of angioimmunoblastic T-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2009 Aug;38(8):552-4
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunophenotype analysis on neoplastic cells in bone marrow and peripheral blood of angioimmunoblastic T-cell lymphoma].
  • [MeSH-major] Bone Marrow Cells / pathology. Immunoblastic Lymphadenopathy / pathology. Immunophenotyping / methods. Lymphoma, T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021969.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD28; 0 / Antigens, CD4; 0 / Antigens, CD95; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down






Advertisement